Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Sei Investments Co.

Key Points

• Sei Investments increased its Jazz Pharmaceuticals stake by 33.4% in the first quarter, purchasing 36,870 additional shares. Institutional investors and hedge funds collectively own 89.14% of the company.
• Analyst sentiment remains positive: Jazz has an average “Moderate Buy” rating and a consensus price target of $259.06, with several firms recently raising targets and UBS upgrading the stock to “buy.”
• JAZZ opened at $255.43, near its 52-week high of $257.00. The company reported quarterly revenue of $1.07 billion and EPS of $6.34, while insiders have sold roughly $3.13 million in shares over the past 90 days.

Sei Investments Co. increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 33.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 147,270 shares of the specialty pharmaceutical company's stock after buying an additional 36,870 shares during the period. Sei Investments Co. owned about 0.23% of Jazz Pharmaceuticals worth $27,844,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Ruffer LLP acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $2,425,000. Allianz Asset Management GmbH raised its position in shares of Jazz Pharmaceuticals by 68.2% in the 4th quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company's stock valued at $101,801,000 after purchasing an additional 242,892 shares in the last quarter. Capricorn Fund Managers Ltd acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $1,700,000. Swedbank AB increased its stake in shares of Jazz Pharmaceuticals by 2.7% in the fourth quarter. Swedbank AB now owns 1,102,974 shares of the specialty pharmaceutical company's stock worth $187,506,000 after buying an additional 28,882 shares during the last quarter. Finally, Fieldview Capital Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $1,864,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Barclays upped their price target on shares of Jazz Pharmaceuticals from $253.00 to $260.00 and gave the company an "overweight" rating in a report on Tuesday, July 14th. Sanford C. Bernstein reissued a "market perform" rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Leerink Partners upped their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an "outperform" rating in a research note on Wednesday, April 22nd. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price target for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Finally, Wells Fargo & Company lifted their price target on Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $259.06.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $255.43 on Tuesday. The firm has a market cap of $16.05 billion, a price-to-earnings ratio of -12,765.12, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $257.00. The company's 50-day moving average price is $237.89 and its 200 day moving average price is $204.06. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Mark Douglas Smith sold 1,157 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the transaction, the director owned 9,680 shares in the company, valued at $2,231,724. The trade was a 10.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total value of $1,442,820.00. Following the transaction, the director owned 366,682 shares of the company's stock, valued at approximately $88,176,020.54. The trade was a 1.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.